Altimmune Q3 2020 Earnings Report
Key Takeaways
Altimmune reported financial results for the third quarter ended September 30, 2020, with a revenue of $2.9 million and a net loss of $17.8 million, or $0.54 net loss per share. The company had cash, cash equivalents, and short-term investments of $206.8 million at the end of the quarter.
Announced positive preclinical results for AdCOVID
Initiated a Phase 1/2 clinical trial of T-COVID; program funded by $4.7 million award from the Department of Defense
Received regulatory clearance to commence a Phase 1 clinical trial of ALT-801 in Australia; Phase 1 trial expected to begin Q4 2020
Secured approximately $200 million in gross proceeds to advance pipeline candidates
Altimmune
Altimmune
Altimmune Revenue by Segment
Forward Guidance
Altimmune provided forward-looking statements regarding the impact of COVID-19 on business operations, clinical trials and results of operations, the timing of key milestones for clinical assets, and the prospects for regulatory approval.